Chen Qi-Feng, Chen Song, Zhao Ming
Department of Minimally Invasive Interventional Therapy, Liver Cancer Study and Service Group, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, People's Republic of China.
State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, Guangdong, People's Republic of China.
J Hepatocell Carcinoma. 2025 Apr 30;12:841-854. doi: 10.2147/JHC.S514881. eCollection 2025.
Hepatocellular carcinoma (HCC) represents a highly aggressive form of liver neoplasm that presents various therapeutic obstacles. Recently, the synergistic use of transarterial chemoembolization (TACE) in conjunction with immunotherapy has attracted considerable interest within the medical community. This review aims to explore the synergistic mechanisms between TACE and immunotherapy, analyze the current research evidence, and discuss their potential applications in the treatment of HCC. By examining how TACE can enhance the efficacy of immunotherapy, we seek to provide direction for future research and emphasize the importance of personalized treatment strategies in managing HCC.
肝细胞癌(HCC)是一种极具侵袭性的肝脏肿瘤,存在多种治疗障碍。最近,经动脉化疗栓塞术(TACE)与免疫疗法的联合使用在医学界引起了相当大的关注。本综述旨在探讨TACE与免疫疗法之间的协同机制,分析当前的研究证据,并讨论它们在HCC治疗中的潜在应用。通过研究TACE如何提高免疫疗法的疗效,我们旨在为未来的研究提供方向,并强调个性化治疗策略在HCC管理中的重要性。